Reviewer's report

Title: FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer: results from FIRGEM study

Version: 2 Date: 8 April 2014

Reviewer: Ali Shamseddine

Reviewer's report:

The manuscript entitled “FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer: results from FIRGEM study” was read and reviewed.

The manuscript tackles a topic that is relevant in the field of pancreatic cancer with sound data. It is clearly outlined and well reported.

# The abstract is a clear reflective summary of the article.
# The introduction provides a good review of the literature concerning the topic. It also gives the rationale behind the choice of the study.
# The Methods section is clear and organized.
# The data is sound and well reported. The tables and the figures provide a very good illustration of the results.
# The discussion addresses very important issues related to the question posed. It summarizes the key results, addresses the limitations of the study and provides a cautious interpretation of the study.
# The conclusion provides a brief summary of the discussion and opens a window for future ideas.

However, it needs minor revisions that are further explained below.

1. The title indicates that the manuscript will be addressing the FIRGEM study and its results whereas it is not the case.
2. The study design should be specified i.e. if it is a prospective observational or interventional. And if it is observational, it should be more specified as well if it is a cohort or a case-control, etc. This should be done in all the sections of the manuscript, especially in the abstract and the methods.
3. The manuscript needs minor editing in language.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: Yes, and I have assessed the statistics in my report.
Declaration of competing interests:

I declare I have no competing interests.